Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of clinical laboratory service Bio-Reference Laboratories
So what: For the quarter, Bio-Reference recorded a 25% increase in profits to $0.45 on a 16% rise in revenue to $172.3 million. Although EPS was $0.02 above expectations, total sales came in $1.4 million shy of Wall Street's expectations. Furthermore, Bio-Reference's guidance of 15% revenue growth and "around 20%" net income growth failed to impress investors.
Now what: Is anyone really that surprised? In mid-July, Quest Diagnostics
Craving more input? Start by adding Bio-Reference Laboratories to your free and personalized watchlist so you can keep up on the latest news with the company.